Nelfinavir

CHEMBL584 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
567.8 g/mol
LogP
5.7
Phase
4

This protease inhibitor antiviral medication is used as part of combination therapy to treat HIV infection. It works by blocking an enzyme that HIV needs to produce mature, infectious viral particles, thereby reducing the amount of virus in the body.

Berat Molekul

567,8000 g/mol

LogP

5,70

TPSA

127,00 Ų

Lipinski RO5

Gagal

Area Terapeutik

Mekanisme Kerja

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C

InChI

InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1

Molecular Formula

C32H45N3O4S

HBD / HBA

4 / 6

Ikatan yang Dapat Dirotasi

10

Atom Berat

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This protease inhibitor antiviral medication is used as part of combination therapy to treat HIV infection. It works by blocking an enzyme that HIV needs to produce mature, infectious viral particles, thereby reducing the amount of virus in the body.

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Yes, Nelfinavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL584. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 64143. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.